AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.
Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cells for treatment of leukemia and lymphoma. Consequently, there is now rapid growth in research on the therapeutic uses of CAR-T cells.
Increasingly CAR-T cell therapies are being employed as a strategy to redirect a patient’s T-cells to target and destroy specific tumor cells. Researchers have found that viral vectors are the most effective way of transducing CAR into T cells as part of a CAR-T cell manufacturing process.
Due to their ability to stably integrate large DNA inserts, and to efficiently transduce both dividing and non-dividing cells, AMSBIO’s new range of clinical grade CAR lentivirus offers the perfect tool to generate CAR-T cells ex-vivo.
A comprehensive line of CAR lentivirus products is now available from AMSBIO optimized to suit almost any research application. For immunotherapy researchers looking to maximize timelines, AMSBIO can deliver ready-to-transduce CAR lentivirus of up to 10e9 IFU/ml.
For further information please visit https://www.amsbio.com/car-t-cell-research/#1684139755204-0c209941-9ce7 or contact the company on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com. At the forefront of providing tools for cancer research, AMSBIO has an extensive and growing portfolio of experimental cell lines, recombinant proteins, and screening services to advance the search for new CAR-T cell therapies.
